Acromegaly Patients Suffer Despite Biochemical Control, Review Finds
A comprehensive review reveals that fatigue, pain, and impaired quality of life persist in acromegaly patients even after hormones are normalized.
Summary
A new review in the Journal of Clinical Endocrinology and Metabolism examines the full burden of living with acromegaly, a condition caused by excess growth hormone and IGF-1. Even when blood markers are controlled through surgery, medication, or radiation, many patients continue to suffer from fatigue, joint pain, sleep problems, depression, and anxiety. The review highlights a troubling gap between biochemical remission and how patients actually feel day-to-day. Treatment itself adds burden through injections, gastrointestinal side effects, and financial strain. The authors call for routine use of validated patient-reported outcome tools and more patient-centered, multidisciplinary care to address the full scope of what acromegaly patients experience.
Detailed Summary
Acromegaly is a rare but serious hormonal disorder in which a pituitary tumor causes the body to overproduce growth hormone and insulin-like growth factor 1 (IGF-1). The resulting excess drives progressive changes across multiple organ systems, including skeletal overgrowth, metabolic dysfunction, cardiovascular complications, and significant psychological distress. While treatments exist — including surgery, somatostatin receptor ligands, dopamine agonists, and radiation — achieving biochemical control does not reliably translate into patient wellbeing.
This review, published in JCEM, synthesizes evidence from clinical trials, longitudinal cohorts, registry studies, and patient-reported outcome (PRO) research to paint a comprehensive picture of the acromegaly patient experience. The authors examined physical symptoms, health-related quality of life (HRQoL), mood, social functioning, work productivity, and financial burden across treatment modalities.
Key findings are striking: fatigue, musculoskeletal pain, arthropathy, sleep disturbance, and body-image concerns are highly prevalent and frequently persist even after biochemical remission is achieved. Depression and anxiety affect a substantial proportion of patients, and treatment-related factors — including injection frequency, breakthrough symptoms between doses, gastrointestinal side effects, and the financial and surveillance demands of long-term management — further erode quality of life and productivity.
The review evaluates several validated PRO instruments, including the Acromegaly Quality of Life Questionnaire and the Acromegaly Symptom Diary, and highlights a consistent discordance between lab values and patient-reported outcomes. This gap underscores the inadequacy of relying solely on biochemical markers to assess treatment success. Emerging oral therapies and long-acting formulations may reduce injection burden, but comparative PRO data remain limited.
The authors conclude that patient-centered acromegaly care requires systematic integration of PRO assessment, multidisciplinary comorbidity management, and shared decision-making. For clinicians, this review is a call to look beyond IGF-1 levels and engage with the lived experience of their patients.
Key Findings
- Fatigue, joint pain, and sleep disturbance persist in many acromegaly patients even after biochemical remission is achieved.
- Depression and anxiety affect a substantial proportion of acromegaly patients across all treatment types.
- Injection burden, breakthrough symptoms, and financial strain significantly reduce patient wellbeing and work productivity.
- Validated PRO tools consistently reveal a gap between normalized hormone levels and actual patient-reported quality of life.
- Emerging oral therapies may reduce treatment burden, but comparative quality-of-life data are currently limited.
Methodology
This is a narrative review synthesizing data from clinical trials, longitudinal cohort studies, registry studies, and patient-reported outcome research. The authors evaluated multiple validated PRO instruments specific to acromegaly. No original data were collected; conclusions are drawn from existing published literature.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. As a narrative review, it is subject to selection bias and does not provide quantitative pooled effect sizes. Comparative PRO data across treatment modalities remain limited, constraining definitive conclusions about which therapies best preserve quality of life.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.